Tezosentan shows potential for treating heart failure

Tezosentan, the first of a new class of drugs called endothelin receptor antagonists, may help stabilise patients with acute decompensated heart failure without the adverse effects associated with traditional therapies. Detailed results from the Randomized Intravenous TeZosentan (RITZ)-2 study demonstrating the haemodynamic benefits of this novel drug were presented at the 50th Annual Scientific Session of the American College of Cardiology [Orlando, US; March 2001].